Imexhs Ltd · ASX:IME
Imexhs — H1 2021 Earnings Presentation
31 slides from Imexhs's earnings presentation, Aug 30, 2021
Slide 1: 1H FY21 Results
Built by physicians for physicians 1H FY21 Results 30 August 2021
Slide 2: Innovative provider of cloud-based, AI medical imaging software solutions
Innovative provider of cloud-based, AI medical imaging software solutions IMEXHS LTD (ASX:IME) | 1H FY21 RESULTS 2
Slide 3: Expanding global footprint
Expanding global footprint Spain 15 countries USA 310 sites Mexico 2,100+ radiologists Honduras El Salvador Nicaragua Australia Costa Rica Panama Colombia 25 distributors Ecuador Peru Brazil Bolivia ~95% Paraguay customer retention Chile Uruguay IMEXHS currently operating 38 Argentina Agreement bein
Slide 4: Agenda
Agenda 1. 1H FY21 Results Overview – Dr German Arango, CEO 2. 1H FY21 Financials – Reena Minhas, CFO 3. Strategy & Outlook – Dr German Arango, CEO 4
Slide 5: 1H FY21 Results Overview
ime x<Hs 1H FY21 Results Overview
Slide 6: 1H FY21 Financial Highlights
1H FY21 Financial Highlights Sales Revenue Annual Recurring Revenue EBITDA $5.2m $12.7m ($2.1m) Up 15% yoy (up 25% on a Up 44% yoy (up 57% on a vs ($1.3m) in 1H FY20 due to constant currency basis) constant currency basis) increased investment in operations Recurring revenue Closing cash Underlying
Slide 7: Aquila Custom
Aquila Custom • Customised solutions for radiology, includes hardware and reporting if required Annualised Recuring Revenue ($m) • Enterprise imaging platform tailored to a customer’s specific needs +32% +22% 12.0 10.7 10.7 • Dedicated to large university hospitals and multi-site 10.0 8.8 healthcare
Slide 8: Aquila in the Cloud (AiC)
Aquila in the Cloud (AiC) • Standardised radiology solution launched in May 2020 • Provides small and medium-sized customers with low-cost, rapidly deployed product offering • At 30 June 2021, 84 deals signed with ARR contribution of $2.0m • 6 deals in the US and 4 in Australia • Distribution via gr
Slide 9: 1H FY21 Financials
ime x<Hs 1H FY21 Financials
Slide 10: Strong growth in ARR
Strong growth in ARR ARR as at 30 June 2021 • $12.7m, up 44% vs pcp (57% on a constant currency basis) • Includes $2.0m from Aquila in the Cloud (AiC) - 84 contract wins including 6 in the US and 4 in Australia Constant currency basis assumes that historic results are converted at the 30 Jun-21 exch
Slide 11: Income Statement
Income Statement $'000 1H FY21 1H FY20 Var Var % • Revenue of $5.2m, up 15% with Revenue 5,159 4,492 667 15% 94% recurring revenue Other revenue 74 79 (5) (6%) • Total expenses of $8.0m, up 16% Total revenue 5,233 4,571 662 14% on pcp, reflect increased Expenses (8,008) (6,933) (1,075) 16% investmen
Slide 12: Balance Sheet
Balance Sheet $'000 Jun 21 Dec 20 Jun 20 Cash 8,342 10,796 6,293 • Strong financial position with closing cash Trade & other receivables 4,609 4,059 3,191 of $8.3m and net assets of $13.7m at 30 June 2021 Inventories 197 390 470 Current assets 13,148 15,245 9,954 • Total debt of $1.0m Non-current as
Slide 13: Summary Cash Flow
Summary Cash Flow $'000 1H21 1H20 Net cash used in operating activities (1,566) (1,063) • 1H FY21 operating outflows up $0.5m reflecting increased Net cash used in investing activities (1,207) (980) investment in sales and Net cash flow from financing activities 361 1,219 marketing, expanding operat
Slide 14: Strategy & Outlook
ime x<Hs Strategy & Outlook
Slide 15: Global market opportunity
Global market opportunity • IMEXHS’s main market is currently RIS/PACS Market 1 Colombia, third largest LATAM country • 85% of AiC3 deals Put bulletfrom outside Colombia points 2019 US$2.8bn • and text here US accounts for ~40% of the global radiology imaging systems (RIS) and PACS 2027 US$5.4bn • m
Slide 16: Industry trends and strategic priorities
INDUSTRY TRENDS: Healthcare IT sector Increasing use of Increased proportion Large, growing but radiological Chronic global of the value chain Shift from client highly fragmented techniques in wider radiologist shortage coming from server architecture to global medical clinical applications, driving
Slide 17: 2021 Product Roadmap
2021 Product Roadmap AQUILA 4.0 with new Alula Marketplace, the Other medical verticals AI Algorithms features and functions world’s first dedicated • Dental Imaging • Automatic detection and orientated to US and pathology marketplace platform segmentation of lung Australian markets workflow program
Slide 18: Developing AI capabilities
Developing AI capabilities • Images almost doubled to 940m reflecting Number of Images Stored (m) full year of Colsubsidio contract 940 • Important test bed for the development and training of AI tools • Developed Stella AI engine which 488 integrates own and third party AI algorithms including ches
Slide 19: Proposed acquisition of RIMAB
Proposed acquisition of RIMAB • IMEXHS to acquire RIMAB SAS, a radiology • Strengthens customer offering and services provider, for COP24.3bn (~A$8.5m1) provides a test bed for developing AI tools less estimated purchase price adjustments • Removes related party transactions and • Purchase price com
Slide 20: About RIMAB SAS
About RIMAB SAS • Provides radiology services to hospitals ~40 radiologists and medical facilities in Colombia and highly skilled teleradiology to Heath Time in Spain workforce 2020 Revenue • Co-founded in 2012 by IMEXHS CEO Dr German Arango A$9.0m • RIMAB and IMEXHS have several clients in Up 60% 1
Slide 21: RIMAB 1H FY21 Update
RIMAB 1H FY21 Update • RIMAB H1 FY21 revenue of ~$A5.3m, up • Subject to approval of acquisition at the 40% yoy, and EBITDA of~A$0.7m, up 25% Extraordinary General Meeting, IMEXHS yoy, (unaudited)(1)(2) Q4 FY21 will include RIMAB results from ~1 October 2021 • Recent achievements include the renewal
Slide 22: FY2021 Outlook
FY2021 Outlook Aquila Custom - strong near-term US expansion – building presence with pipeline for larger customised AiC, sales team investment and via online solutions marketplaces Aquila in the Cloud (AiC) – strong Investing in growth – Sales, technology underlying demand and development and opera
Slide 23: ime xHs
ime xHs
Slide 24: Appendix
ime xHs Appendix
Slide 25: Our competitive advantage
Our competitive advantage ACCESSIBILITY CAPABILITY FLEXIBILITY AFFORDABILITY • Fully web & cloud-based • Single platform and • Multi-modality • Lower cost base than • Teleradiology accessed archiving system • Scalable modular solutions competitors from any device or browser • Multi-tenant architectu
Slide 26: IMEXHS medical imaging platform
IMEXHS medical imaging platform Advanced Stella Vital Alma Braviz Post-processing AI 3D ADv 3D Basic Enterprise Aquila Alula Anteros Imaging Radiology Pathology Cardiology Core Platform HIRUKOTM Universal Portals Multi-Tenancy PACS/VNA Viewer Nuance 360 IMEXHS LTD (ASX:IME) | 1H FY21 RESULTS Note: C
Slide 27: End-to-end modular imaging solution
End-to-end modular imaging solution Scan scheduled via our platform Uploaded to our platform Archived on our cloud-based platform Manages Billing } 1)Business Intelligence 2)Statistical Data 3. 4. 5. 1. 2. Radiologist Referring Physician Billing Physician Patient has interprets scanned reviews image
Slide 28: Range of solutions for AiC customers
Range of solutions for AiC customers LITE PRO ULTIMATE Multiplatform Unlimited Users Unlimited Exams 100% Web Platform Modality Worklist Scheduling Management VNA | PACS Archiving SMS notifications Digital Signature in Reports Web Viewer Patient Admission VR Web (Reporting) (*) Results Distribution
Slide 29: Multiple distribution channels
Multiple distribution channels • Distributor partners represent important • New distribution channel on Ingram’s Micro sales channel for both Aquila Custom and Cloud marketplace Aquila in the Cloud DISTRIBUTION CHANNELS DIRECT SALES DISTRIBUTORS • Several markets • Agreements with distributor partne
Slide 30: Glossary
Glossary Artificial intelligence (AI) tools aid the Medical verticals are market segments Streaming technology transfers medical interpretation of radiological images that refer to specific diagnostic images from our VNA to our Web Viewer, which require access to large image departments within hospi
Slide 31: Disclaimer
Disclaimer The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants (“Information”) is provided to the Recipient on the terms and co